BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Cantor Fitzgerald Analyst Says

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its target price increased by stock analysts at Cantor Fitzgerald from $24.00 to $26.00 in a report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price would suggest a potential upside of 286.90% from the stock’s current price. Cantor Fitzgerald also issued estimates for BioCryst Pharmaceuticals’ FY2025 earnings at $0.05 EPS.

Several other research analysts have also weighed in on BCRX. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. TD Cowen began coverage on BioCryst Pharmaceuticals in a research report on Wednesday. They issued a “buy” rating and a $30.00 target price on the stock. Evercore ISI reaffirmed an “in-line” rating and issued a $8.00 target price on shares of BioCryst Pharmaceuticals in a research report on Wednesday, October 1st. Needham & Company LLC upped their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Wedbush upped their target price on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the stock an “outperform” rating in a research report on Monday, June 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.18.

BioCryst Pharmaceuticals Trading Down 1.3%

Shares of BioCryst Pharmaceuticals stock opened at $6.72 on Wednesday. The stock has a 50-day moving average price of $7.87 and a 200 day moving average price of $8.64. The company has a market cap of $1.41 billion, a P/E ratio of -37.33, a P/E/G ratio of 1.43 and a beta of 1.05. BioCryst Pharmaceuticals has a 1 year low of $6.00 and a 1 year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.12. The business had revenue of $163.35 million during the quarter, compared to analysts’ expectations of $149.59 million. During the same period in the prior year, the company posted ($0.06) earnings per share. The firm’s revenue was up 49.5% on a year-over-year basis. On average, equities analysts forecast that BioCryst Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Theresa Heggie sold 70,000 shares of the stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total transaction of $595,700.00. Following the completion of the sale, the director owned 65,352 shares in the company, valued at $556,145.52. This represents a 51.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC increased its holdings in BioCryst Pharmaceuticals by 1,161.8% during the 1st quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 5,449 shares in the last quarter. SG Americas Securities LLC lifted its holdings in BioCryst Pharmaceuticals by 5.2% during the first quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 2,146 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of BioCryst Pharmaceuticals by 113.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company’s stock valued at $283,000 after purchasing an additional 20,043 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the first quarter valued at about $79,000. Finally, Cerity Partners LLC increased its position in shares of BioCryst Pharmaceuticals by 203.6% in the first quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company’s stock valued at $273,000 after acquiring an additional 24,418 shares during the last quarter. Institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.